Randomized Clinical Trial (RCT) to Compare the Efficacy of Coban 2 Versus SSB in the Treatment of Venous Leg Ulcers

Inclusion Criteria: * Males or females, age 18 years or older * Subjects having a venous leg ulcer (stage C6 according CEAP classification, venous pathology proved by the presence of reflux (Pr)), which is at least 1 cm in any dimension but not larger than 10 cm in any dimension and has at least 5 cm distance to additional ulcers. * Subjects who are co-operative, willing to give written informed consent prior to study entry, and willing to comply with the study protocol. * Subjects who are able to understand and answer questionnaire items. * Subjects who can walk (with or without a walking aid). * Subjects who have an ABPI (ankle brachial pressure index) of treated leg greater or equal to 0,8 as measured within four weeks prior to enrollment. * Subjects with venous incompetence as defined by reflux longer than 1,0 second in at least one of the following sites: groin \[femoral vein, junction of GSV\], mid thigh medial \[GSV\], hollow of the knee \[popliteal vein, junction of SSV\], mid calf \[SSV\] in the standing position, measured by Doppler, preferably by duplex within the last 12 month without following active treatment of venous reflux. Exclusion Criteria: * Subjects with an ABPI \< 0.8 as measured within four weeks prior to enrollment. * Subjects whose condition, in the opinion of the investigator, does not require or allow for compression therapy. * Subjects where the potential study ulcer is infected, i.e. showing signs of clinical infection (not contamination) as evidenced by purulent, malodorous, or recent increase in drainage and/or peri-wound erythema or elevated temperature. * Subjects receiving any systemic antibiotics. * Subjects with diagnosed cancerous ulceration. * Subjects with diabetic foot ulcers (do not exclude diabetics). * Subjects with circumferential wounds. * Subjects who started or significantly changed treatment with mood altering substances (e.g. antidepressant drugs) within two weeks prior to enrollment. * Subjects who are participating in any prospective clinical study that can potentially interfere with this study. * Subjects who are, in the opinion of the clinical investigator, unsuitable for enrollment in this study, for reasons not specified in the exclusion criteria. * Subjects with known allergies against the following products: Coban 2 Layer Compression System, Rosidal K, Rosidal soft, Tegaderm Foam, Cavilon NSBF